States sue Biden over COVID vaccine mandate

President Joe Biden is facing major backlash following a COVID-19 vaccine mandate.

After at least two dozen states filed lawsuits against the rule, a federal appeals court has blocked it. The rule mandates all private employers with more than 100 employees to require all employees to be vaccinated against COVID-19 by Jan. 4, 2022, or test weekly for the virus. Employers are also required to mandate masks for unvaccinated employees by Dec. 5.

With the rule on pause at the moment, the trajectory of the mandate is uncertain. Several healthcare companies have already implemented their own vaccine mandates, though a portion of healthcare professionals have noted they won’t get vaccinated. Some healthcare providers have struggled with the decision whether or not to require vaccination for staff.

The court decision that paused the rule was made by the 5th Circuit Court of Appeals, which stated the states suing "give cause to believe there are grave statutory and constitutional issues with the Mandate,” NPR reported. There are multiple lawsuits across the courts that will likely be consolidated in the coming weeks.

However, even with the pause––and potential for the rule to be permanently shut down in the courts––many healthcare companies and larger companies outside the healthcare industry are likely to take up the mandate on their own.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.